CJ
Jandus, Camilla
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer | Nature communications | 2026 | 6 | 3 | |||
| STAT1 and STAT4 expression as prognostic biomarkers in patients with bladder cancer | Molecular and clinical oncology | 2025 | 39 | 50 | |||
| Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancer | Science advances | 2025 | 90 | 203 | |||
| Neural anticipation of virtual infection triggers an immune response | Nature neuroscience | 2025 | 45 | 28 | |||
| Treatment of Advanced NSCLC Patients with an Anti-Idiotypic NeuGcGM3-Based Vaccine : Immune Correlates in Long-Term Survivors | Biomedicines | 2025 | 30 | 40 | |||
| Circulating innate lymphoid cells are dysregulated in patients with prostate cancer | Cellular & Molecular Biology Letters | 2025 | 37 | 17 | |||
| Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies | Journal for immunotherapy of cancer | 2025 | 49 | 23 | |||
| Noncanonical NF-κB signaling in dendritic cells is required for ATP-driven indoleamine 2,3-dioxygenase 1 induction through P2Y11 receptor | Journal of leukocyte biology | 2025 | 41 | 73 | |||
| Lymphatic-derived oxysterols promote anti-tumor immunity and response to immunotherapy in melanoma | Nature communications | 2025 | 72 | 26 | |||
| PD-1+ NK cell subsets in high grade serous ovarian cancer: an indicator of disease severity and a target for combined immune-checkpoint blockade | Journal of experimental & clinical cancer research | 2025 | 24 | 32 | |||
| UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity | Cell reports medicine | 2025 | 37 | 48 | |||
| Effects of Intravenous Immunoglobulins on Human Innate Immune Cells: Collegium Internationale Allergologicum Update 2024 | International archives of allergy and immunology | 2024 | 44 | 0 | |||
| Robust estimation of cancer and immune cell-type proportions from bulk tumor ATAC-Seq data | eLife | 2024 | 83 | 41 | |||
| The landscape of combining immune checkpoint inhibitors with novel Therapies : Secret alliances against breast cancer | Cancer treatment reviews | 2024 | 49 | 27 | |||
| Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy | Cell | 2024 | 975 | 287 | |||
| Methionine oxidation selectively enhances T cell reactivity against a melanoma antigen | iScience | 2023 | 273 | 145 | |||
| Assessing the impact of persistent HIV infection on innate lymphoid cells using in vitro models | ImmunoHorizons | 2023 | 143 | 178 | |||
| Circulating extracellular particles from severe COVID-19 patients show altered profiling and innate lymphoid cell-modulating ability | Frontiers in immunology | 2023 | 115 | 65 | |||
| Dendritic cells direct circadian anti-tumour immune responses | Nature | 2023 | 792 | 210 | |||
| Dynamic single-cell regulomes characterize human peripheral blood innate lymphoid cell subpopulations | iScience | 2023 | 159 | 55 | |||
| IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia | Haematologica | 2023 | 120 | 78 | |||
| High-throughput spatiotemporal monitoring of single-cell secretions via plasmonic microwell arrays | Nature biomedical engineering | 2023 | 111 | 142 | |||
| Dampening of cytotoxic innate lymphoid cells: A new tumour immune escape mechanism in B cell non-Hodgkin's lymphoma | Cellular immunology | 2022 | 319 | 166 | |||
| Gliadin-reactive vitamin D-sensitive proinflammatory ILCPs are enriched in celiac patients | Cell reports | 2022 | 246 | 178 | |||
| The era of cytotoxic CD4 T cells | Frontiers in immunology | 2022 | 214 | 258 | |||
| Development of human ILCs and impact of unconventional cytotoxic subsets in the pathophysiology of inflammatory diseases and cancer | Frontiers in immunology | 2022 | 248 | 262 | |||
| Randomized double-blind clinical study in patients with COVID-19 to evaluate the safety and efficacy of a phytomedicine (P2Et) | Frontiers in medicine | 2022 | 239 | 129 | |||
| c-Maf enforces cytokine production and promotes memory-like responses in mouse and human type 2 innate lymphoid cells | EMBO journal | 2022 | 384 | 470 | |||
| Static adhesion assay for human peripheral blood mononuclear cells | Bio-protocol | 2022 | 251 | 229 | |||
| PPARɣ drives IL-33-dependent ILC2 pro-tumoral functions | Nature Communications | 2021 | 357 | 266 | |||
| Healthy and patient type 2 innate lymphoid cells are differently affected by in vitro culture conditions | Journal of Asthma and Allergy | 2021 | 247 | 88 | |||
| Immune checkpoint and telomerase crosstalk is mediated by miRNA-138 in bladder cancer | Frontiers in oncology | 2021 | 326 | 104 | |||
| Editorial: memory T cells in chronic infections and tumors | Frontiers in Immunology | 2021 | 207 | 134 | |||
| c-Met enforces proinflammatory and migratory features of human activated CD4+ T cells | Cellular & Molecular Immunology | 2021 | 338 | 224 | |||
| A new workflow combining magnetic cell separation and impedance-based cell dispensing for gentle, simple and reliable cloning of specific CD8+ T cells | SLAS technology | 2021 | 279 | 202 | |||
| Severe COVID-19 patients exhibit an ILC2 NKG2D+ population in their impaired ILC compartment | Cellular & Molecular Immunology | 2021 | 245 | 132 | |||
| Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer | Science Advances | 2021 | 496 | 363 | |||
| Human primed ILCPs support endothelial activation through NF-κB signaling | eLife | 2021 | 356 | 198 | |||
| Sharpening of peripersonal space during the COVID-19 pandemic | Current Biology | 2021 | 240 | 246 | |||
| Impact of immunotherapy on CD4 T cell phenotypes and function in cancer | Vaccines | 2021 | 260 | 190 | |||
| Optimized combinatorial pMHC class II multimer labeling for precision immune monitoring of tumor-specific CD4 T cells in patients | Journal for immunotherapy of cancer | 2020 | 583 | 306 | |||
| Distinct and shared gene expression for human innate versus adaptive helper lymphoid cells | Journal of Leukocyte Biology | 2020 | 412 | 272 | |||
| Detecting and analyzing murine innate lymphoid cells | Tumor Immunology and Immunotherapy: Cellular Methods Part A | 2020 | 347 | 0 | |||
| Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion | Nature Immunology | 2020 | 433 | 1 | |||
| Native/citrullinated LL37-specific T-cells help autoantibody production in systemic lupus erythematosus | Scientific Reports | 2020 | 354 | 156 | |||
| CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors | Nature Immunology | 2020 | 537 | 7 | |||
| Immune system activation by natural products and complex fractions: a network pharmacology approach in cancer treatment | Cell Stress | 2020 | 341 | 188 | |||
| Immunosuppressive mediators impair proinflammatory innate lymphoid cell function in human malignant melanoma | Cancer Immunology Research | 2020 | 621 | 4 | |||
| Cancer immunotherapy by blocking immune checkpoints on innate lymphocytes | Cancers | 2020 | 390 | 250 | |||
| The pro- and anti-tumor role of ILC2s | Seminars in Immunology | 2019 | 350 | 0 | |||
| MicroRNA-155 expression is enhanced by T-cell receptor stimulation strength and correlates with improved tumor control in melanoma | Cancer Immunology Research | 2019 | 304 | 1 | |||
| ILC2s: new actors in tumor immunity | Frontiers in Immunology | 2019 | 416 | 201 | |||
| High-throughput screening of human tumor antigen-specific CD4 T cells, including neoantigen-reactive T cells | Clinical Cancer Research | 2019 | 450 | 4 | |||
| Immunophenotyping of human innate lymphoid cells | Methods in Molecular Biology | 2019 | 336 | 1 | |||
| Peripheral innate lymphoid cells are increased in first line metastatic colorectal carcinoma patients: a negative correlation with th1 immune responses | Frontiers in Immunology | 2019 | 329 | 151 | |||
| To be a tumor promoting or tumor suppressing ILC: that is the question | Seminars in Immunology | 2019 | 302 | 3 | |||
| Lymphocyte-derived exosomal microRNAs promote pancreatic β cell death and may contribute to type 1 diabetes development | Cell Metabolism | 2019 | 387 | 3 | |||
| The architecture of the IgG anti-carbohydrate repertoire in primary antibody deficiencies | Blood | 2019 | 369 | 3 | |||
| Siglec-9 regulates an effector memory CD8+ T-cell subset that congregates in the melanoma tumor microenvironment | Cancer Immunology Research | 2019 | 333 | 0 | |||
| Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes | Nature Biotechnology | 2019 | 446 | 2 | |||
| CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML | Blood Advances | 2019 | 545 | 253 | |||
| Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells | Journal for Immunotherapy of Cancer | 2019 | 369 | 177 | |||
| Human innate lymphoid cells (ILCs): Toward a uniform immune-phenotyping | Cytometry. Part B, Clinical cytometry | 2018 | 425 | 166 | |||
| Innate lymphoid cells in antitumor immunity | Journal of Leukocyte Biology | 2018 | 293 | 0 | |||
| Induction of paracrine signaling in metastatic melanoma cells by PPARγ agonist rosiglitazone activates stromal cells and enhances tumor growth | Cancer Research | 2018 | 364 | 0 | |||
| Autocrine adenosine regulates tumor polyfunctional CD73+CD4+ effector T cells devoid of immune checkpoints | Cancer Research | 2018 | 358 | 0 | |||
| Inhibition of membrane-bound BAFF by the anti-BAFF antibody belimumab | Frontiers in Immunology | 2018 | 348 | 205 | |||
| ATP release from chemotherapy-treated dying leukemia cells elicits an immune suppressive effect by increasing regulatory T cells and tolerogenic dendritic cells | Frontiers in Immunology | 2017 | 317 | 190 | |||
| Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis | OncoImmunology | 2017 | 405 | 0 | |||
| ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence | Journal of Clinical Investigation | 2017 | 405 | 207 | |||
| Dysregulated Innate Lymphocytes in Patients With Primary Antibody Deficiency Treated With Intravenous Immunoglobulin | Journal of Investigational Allergology and Clinical Immunology | 2017 | 530 | 1 | |||
| Identification of innate lymphoid cells in single-cell RNA-Seq data | Immunogenetics | 2017 | 367 | 3 | |||
| The vast universe of T cell diversity: subsets of memory cells and their differentiation | Methods in Molecular Biology | 2017 | 341 | 0 | |||
| Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis | Nature Communications | 2017 | 682 | 222 | |||
| NLRC5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions | Nature Communications | 2016 | 325 | 132 | |||
| Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope | OncoImmunology | 2016 | 348 | 1 | |||
| Modulation of mTOR signalling triggers the formation of stem cell-like memory T cells | EBioMedicine | 2016 | 372 | 144 | |||
| Vaccination with long NY-ESO-1 79-108 peptide and CpG-B leads to robust activation of CD4 and CD8 T cell responses in stage III/IV melanoma patients, and a new HLA-DR7 epitope | 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) | 2015 | 2 | 9 | |||
| Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells | International journal of cancer | 2012 | 2 | 0 | |||
| Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts | Cancer research | 2009 | 638 | 0 |
